ALLI: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Haleon Us Holdings	ALLI	orlistat	CAPSULE;ORAL	021887	NDA	Haleon US Holdings LLC	0135-0461-01	60 CAPSULE in 1 BOTTLE (0135-0461-01)	2007-02-07
Haleon Us Holdings	ALLI	orlistat	CAPSULE;ORAL	021887	NDA	Haleon US Holdings LLC	0135-0461-05	120 CAPSULE in 1 BOTTLE (0135-0461-05)	2007-02-07
Haleon Us Holdings	ALLI	orlistat	CAPSULE;ORAL	021887	NDA	Haleon US Holdings LLC	0135-0461-06	170 CAPSULE in 1 BOTTLE (0135-0461-06)	2007-02-07
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the current supplier landscape for ALLI (orlistat), a weight-management drug. It identifies key active pharmaceutical ingredient (API) manufacturers and contract manufacturing organizations (CMOs) involved in its production. The analysis focuses on patent status, manufacturing capabilities, and regulatory approvals to inform R&D and investment decisions.

What is ALLI (Orlistat)?

ALLI, the over-the-counter (OTC) formulation of orlistat, is a lipase inhibitor that works by reducing the absorption of dietary fat in the digestive tract. The prescription-strength version is known as Xenical. Orlistat was developed by Hoffmann-La Roche and has been available in various forms since the late 1990s. The OTC version, ALLI, contains a lower dose (60 mg) compared to the prescription version (120 mg) and is available without a prescription in many markets.

Key Active Pharmaceutical Ingredient (API) Manufacturers

The production of the orlistat API is concentrated among a limited number of manufacturers, primarily in Asia. These companies are critical to the global supply chain for both prescription and OTC orlistat.

Major Orlistat API Suppliers:

Jiangsu Haosen Pharmaceutical Co., Ltd. (China): A significant producer of orlistat API. The company has established production facilities and adheres to international quality standards.
An Said Pharmaceutical Co., Ltd. (China): Another key Chinese supplier of orlistat API. They possess significant manufacturing capacity.
Sumitomo Chemical Co., Ltd. (Japan): While historically involved in drug development, Sumitomo has also been a producer of orlistat API. Their involvement may be more focused on specific markets or proprietary processes.
IOL Chemicals and Pharmaceuticals Limited (India): IOLCP is a prominent Indian pharmaceutical company that manufactures a range of APIs, including orlistat. They have a strong export market and regulatory compliance record.

API Manufacturing Capacity and Trends:

API manufacturing for orlistat is largely driven by cost efficiencies and established production lines. China and India remain dominant due to their lower manufacturing costs and extensive chemical synthesis expertise. The demand for orlistat, though facing competition from newer weight-loss therapies, remains stable, particularly for the OTC market. Suppliers are increasingly focused on Good Manufacturing Practice (GMP) compliance and regulatory documentation to meet the requirements of major pharmaceutical markets such as the US, Europe, and Japan.

Contract Manufacturing Organizations (CMOs) for Finished Dosage Forms

The manufacturing of the finished ALLI drug product, which involves formulating the orlistat API into capsules, is handled by various CMOs. These organizations provide specialized formulation, manufacturing, packaging, and sometimes distribution services.

Prominent CMOs Involved in Orlistat Production:

The exact list of CMOs producing ALLI can fluctuate due to supply agreements and market dynamics. However, companies with broad formulation capabilities for solid oral dosage forms are key players. These include:

Catalent Pharma Solutions: A global leader in drug development and manufacturing solutions, Catalent has extensive experience in producing OTC and prescription medications.
Patheon (part of Thermo Fisher Scientific): Another major global CDMO (Contract Development and Manufacturing Organization) with a wide range of manufacturing capabilities, including softgel and hard-shell capsules.
Aarti Drugs Ltd. (India): While primarily an API manufacturer, Aarti Drugs also has capabilities in finished dosage forms and may engage in contract manufacturing for orlistat.
Kemwell Biopharma: A contract manufacturing company with facilities in Europe and Asia, offering comprehensive services for solid dosage forms.

CMO Selection Criteria:

Pharmaceutical companies selecting CMOs for ALLI production typically evaluate:

Regulatory Compliance: Adherence to FDA, EMA, and other relevant regulatory body standards (cGMP).
Manufacturing Scale and Capabilities: Ability to handle large volumes and specific dosage forms (e.g., 60 mg capsules).
Quality Assurance Systems: Robust quality control and assurance processes.
Cost-Effectiveness: Competitive pricing for manufacturing services.
Supply Chain Security: Reliability and resilience of their supply chain.
Intellectual Property Protection: Confidentiality and data security measures.

Patent Landscape Analysis

The patent landscape for orlistat is mature, with the primary composition of matter patents having long expired. However, patents related to specific formulations, manufacturing processes, and new uses can still impact market exclusivity and generic competition.

Key Patent Expirations and Developments:

Composition of Matter Patents: The original patents covering the orlistat molecule expired globally decades ago, paving the way for generic entry for prescription-strength orlistat.
Formulation Patents: Patents relating to specific delivery systems, excipients, or improved formulations of orlistat have been filed over the years. These can sometimes extend market exclusivity for branded products or create barriers for certain generic approaches. For example, patents might cover methods to improve stability or reduce side effects.
Manufacturing Process Patents: Innovations in the synthesis of the orlistat API or in the manufacturing of the finished dosage form can be patented. These patents are crucial for API manufacturers seeking to protect their proprietary production methods.
Indications and Use Patents: While orlistat is primarily known for weight management, any new, patented indications or novel therapeutic uses could impact its market.

Impact of Patent Expirations on ALLI:

The expiration of core patents has facilitated the availability of generic versions of orlistat globally. For ALLI (the OTC brand), the market dynamics are influenced by the brand's established presence and marketing, alongside competition from generic OTC orlistat products. The lower 60 mg dosage and the OTC status differentiate it from prescription Xenical. Generic manufacturers primarily focus on efficiently producing bioequivalent 60 mg orlistat capsules to compete on price.

Generic Competition and Market Entry:

Generic orlistat has been available for many years. The entry of generic OTC orlistat products has increased competition for ALLI. Manufacturers of generic orlistat focus on obtaining regulatory approvals (e.g., Abbreviated New Drug Applications or ANDAs in the US) by demonstrating bioequivalence to the reference listed drug (ALLI).

Regulatory Approvals and Quality Standards

Operating within the pharmaceutical industry necessitates strict adherence to regulatory guidelines and quality standards. For ALLI and its constituents, this means compliance with agencies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national regulatory bodies.

Key Regulatory Considerations:

Good Manufacturing Practices (GMP): All API manufacturers and CMOs must operate under cGMP. This involves rigorous quality control, documentation, and process validation to ensure product safety, efficacy, and consistency. FDA's 21 CFR Part 210 and 211 are foundational.
Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents detail the manufacturing process, facilities, and quality controls for the API. Pharmaceutical companies can then reference these DMFs in their drug applications.
ANDA Filings: For generic versions of ALLI, companies must submit an ANDA to the FDA, demonstrating that their product is bioequivalent to the reference product and manufactured under cGMP.
Facility Inspections: Regulatory agencies conduct periodic inspections of manufacturing facilities to ensure ongoing compliance. Findings from these inspections can impact a company's ability to supply products to regulated markets.
Impurity Profiles: Manufacturers must control and monitor impurity levels in the API and finished drug product to meet stringent regulatory limits.

Impact of Regulatory Landscape on Suppliers:

Suppliers that can consistently demonstrate compliance with global regulatory standards are favored. Companies with a history of successful FDA or EMA inspections and well-maintained DMFs have a competitive advantage. The increasing complexity of regulatory requirements, particularly concerning data integrity and supply chain traceability, adds to the operational burden and cost for suppliers.

Supply Chain and Geopolitical Considerations

The global nature of pharmaceutical manufacturing means that the supply chain for ALLI involves multiple countries and intricate logistical networks. Geopolitical factors can introduce risks and opportunities.

Key Supply Chain Factors:

Geographic Concentration: A significant portion of orlistat API manufacturing is concentrated in China and India. This concentration creates vulnerabilities to regional disruptions (e.g., natural disasters, pandemics, trade disputes).
Logistics and Transportation: The movement of raw materials, APIs, and finished products across continents requires robust logistics and reliable shipping partners. Global shipping costs and availability can impact overall product costs.
Trade Policies and Tariffs: Changes in international trade policies, tariffs, and import/export regulations can affect the cost and accessibility of raw materials and finished goods.
Raw Material Sourcing: The synthesis of orlistat requires specific chemical precursors. The availability and cost of these precursor chemicals, which are also often sourced globally, can influence API production.
Geopolitical Stability: Political instability or sanctions in key manufacturing regions can disrupt production and supply chains.

Risk Mitigation Strategies:

Pharmaceutical companies often employ strategies to mitigate supply chain risks, including:

Dual Sourcing: Qualifying multiple API manufacturers and CMOs to avoid over-reliance on a single supplier.
Geographic Diversification: Sourcing from manufacturers in different geographical regions to spread risk.
Inventory Management: Maintaining adequate safety stock of critical raw materials and finished goods.
Supplier Audits and Partnerships: Conducting thorough audits of suppliers and fostering strong, transparent relationships.

Market Dynamics and Future Outlook

The market for weight-management drugs is dynamic, influenced by evolving consumer preferences, scientific advancements, and competitive pressures. ALLI (orlistat) faces competition from both generic orlistat products and newer pharmacological agents.

Competitive Landscape:

Generic Orlistat: The availability of lower-cost generic orlistat has significantly impacted the market share of branded ALLI.
Newer Weight-Loss Medications: The development and approval of GLP-1 receptor agonists (e.g., semaglutide, liraglutide) for weight management have introduced potent new therapeutic options, potentially drawing market share away from older medications like orlistat.
Lifestyle Interventions: The continued emphasis on diet, exercise, and behavioral changes as foundational components of weight management.

Future Outlook for ALLI Suppliers:

Stable Demand for OTC: The OTC market for orlistat is expected to remain stable, driven by accessibility and established brand recognition for ALLI. Generic competition will continue to pressure pricing.
Focus on Cost-Effective Manufacturing: API manufacturers and CMOs will continue to prioritize cost-efficiency to remain competitive, especially in supplying generic orlistat.
Regulatory Hurdles: Increased regulatory scrutiny and evolving compliance requirements will necessitate ongoing investment in quality systems for all suppliers.
Innovation in Formulation: While less likely for a mature OTC product, any patented innovations in orlistat formulation that offer improved efficacy or reduced side effects could create new market opportunities. However, the primary driver for suppliers will remain efficient, compliant production of the 60 mg dosage.

Key Takeaways

The global supply chain for ALLI (orlistat) API is concentrated among a few manufacturers, predominantly in China and India, with key players including Jiangsu Haosen Pharmaceutical, An Said Pharmaceutical, Sumitomo Chemical, and IOL Chemicals and Pharmaceuticals.
Finished dosage form manufacturing for ALLI is handled by Contract Manufacturing Organizations (CMOs) such as Catalent Pharma Solutions and Patheon, who possess broad formulation and GMP-compliant production capabilities.
The patent landscape for orlistat is mature, with composition of matter patents expired, allowing for significant generic competition. Focus has shifted to formulation and process patents.
Strict adherence to global regulatory standards, including cGMP and successful FDA/EMA inspections, is paramount for all API manufacturers and CMOs supplying ALLI.
Supply chain risks are amplified by geographic concentration of API production and are subject to geopolitical factors and trade policies.
While ALLI maintains a presence in the OTC weight-management market, it faces increasing competition from generic orlistat and newer pharmacological agents. Suppliers will continue to focus on cost-effective and compliant production.

Frequently Asked Questions

What are the primary regulatory bodies overseeing ALLI manufacturing? The primary regulatory bodies are the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), along with national regulatory authorities in other markets where ALLI is sold.
How does the OTC status of ALLI (60 mg) differ in terms of supplier requirements from prescription Xenical (120 mg)? While both require cGMP compliance, the regulatory pathway for OTC products like ALLI may involve different submission requirements (e.g., monograph compliance or specific OTC drug applications) compared to prescription drugs, although the fundamental quality and manufacturing standards remain high.
Which countries are the largest exporters of orlistat API? China and India are the largest exporters of orlistat API due to their established chemical synthesis infrastructure and cost advantages.
Are there any significant supply chain vulnerabilities for orlistat due to its geographic concentration? Yes, the concentration of API manufacturing in China and India presents vulnerabilities related to geopolitical events, trade disputes, and regional health crises that could disrupt production or export.
What impact do newer weight-loss drugs, such as GLP-1 agonists, have on the suppliers of orlistat? The emergence of highly effective newer weight-loss medications can reduce overall market demand for older drugs like orlistat, potentially leading to decreased production volumes for orlistat API manufacturers and CMOs serving this segment.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-regulation/current-good-manufacturing-practice-cgmp-regulations

[2] European Medicines Agency. (n.d.). Manufacturing of medicines. Retrieved from https://www.ema.europa.eu/en/human-regulatory/overview/manufacturing-medicines

[3] IOL Chemicals and Pharmaceuticals Limited. (n.d.). Product Portfolio. Retrieved from https://www.iolcp.com/products/ (Note: Specific page for Orlistat API may vary)

[4] Sumitomo Chemical Co., Ltd. (n.d.). Pharmaceuticals. Retrieved from https://www.sumitomo-chemical.com/business/pharmaceuticals/ (Note: Specific product details may require deeper search)

[5] Catalent Pharma Solutions. (n.d.). Drug Development & Manufacturing Services. Retrieved from https://www.catalent.com/capabilities/

[6] Thermo Fisher Scientific. (n.d.). Patheon Pharmaceutical Services. Retrieved from https://www.thermofisher.com/us/en/home/brands/patheon.html

[7] U.S. Food and Drug Administration. (n.d.). Abbreviated New Drug Applications (ANDAs) for Generic Drugs. Retrieved from https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas-generic-drugs

Suppliers and packagers for ALLI

ALLI

ALLI Drug Supplier Landscape